Stockscreener 앱 받기
6.30
0.16%
-0.010
시간 외 거래:
6.19
-0.11
-1.75%
전일 마감가:
$6.31
열려 있는:
$6.35
하루 거래량:
2.16M
Relative Volume:
1.13
시가총액:
$2.36B
수익:
$10.53B
순이익/손실:
$-1.23B
주가수익비율:
-1.9409
EPS:
-3.246
순현금흐름:
$949.99M
1주 성능:
+4.30%
1개월 성능:
+10.72%
6개월 성능:
+8.25%
1년 성능:
+4.83%
1일 변동 폭
$6.20
$6.385
1주일 범위
$5.732
$6.385
52주 변동 폭
$4.33
$8.00
Bausch Health Companies Inc Stock (BHC) Company Profile
명칭
Bausch Health Companies Inc
전화
514-744-6792
주소
2150 ST. ELZEAR BLVD. WEST, QUEBEC, QC
Compare BHC vs TAK, TEVA, HLN, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BHC
Bausch Health Companies Inc
|
6.30 | 2.36B | 10.53B | -1.23B | 949.99M | -3.246 |
TAK
Takeda Pharmaceutical Co Adr
|
19.67 | 62.84B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.50 | 48.40B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.13 | 44.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.38 | 32.80B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
533.12 | 22.87B | 3.17B | 1.29B | 1.01B | 27.09 |
Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Equal Weight |
| 2024-08-02 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
| 2024-07-10 | 개시 | Raymond James | Mkt Perform |
| 2023-09-20 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-06-16 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2022-07-29 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-07-29 | 다운그레이드 | Truist | Buy → Hold |
| 2022-07-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-06-13 | 재개 | JP Morgan | Overweight |
| 2021-03-24 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-02-17 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-01-22 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-09-17 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2020-08-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-17 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-24 | 개시 | Citigroup | Buy |
| 2020-04-02 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-29 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2020-01-22 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2019-12-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-12-02 | 개시 | Goldman | Neutral |
| 2019-10-25 | 개시 | Cowen | Outperform |
| 2019-09-12 | 개시 | Guggenheim | Buy |
| 2019-08-15 | 업그레이드 | TD Securities | Hold → Buy |
| 2019-07-19 | 개시 | Wolfe Research | Outperform |
| 2019-06-11 | 재개 | Barclays | Overweight |
| 2019-05-13 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2019-01-02 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-11-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-13 | 업그레이드 | Piper Jaffray | Underweight → Neutral |
모두보기
Bausch Health Companies Inc 주식(BHC)의 최신 뉴스
Bausch + Lomb CEO Saunders departs, Chairman Appio named interim chief - Reuters
Thomas J. Appio Named Interim CEO of Bausch + Lomb as Brent Saunders Departs - VisionMonday.com
What Could Bausch Health (TSX:BHC) Reveal in Its Next Results? - Kalkine Media
Bausch + Lomb CEO Saunders steps down, Chairman Appio appointed interim chief - The Mighty 790 KFGO
Bausch Health study shows improved cirrhosis care adherence By Investing.com - Investing.com Canada
Bausch Health study shows modest gains in cirrhosis care adherence - StreetInsider
Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway - PR Newswire
Bausch + Lomb Names Thomas J. Appio Interim CEO - www.tokenpost.com
Bausch + Lomb names Appio interim CEO as Saunders departs - StreetInsider
Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance - The Globe and Mail
Bausch Health Companies Inc. (BHC) options chain – Yahoo Finance - Yahoo Finance Singapore
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch Health Companies (BHC), Arvinas Holding Company (ARVN) and Ovid Therapeutics (OVID) - The Globe and Mail
At 5 p.m. on Oct. 28, Bausch Health will discuss its Q3 results. - Stock Titan
Bausch Health to Announce Third Quarter 2026 Results on October 28, 2026 - Yahoo Finance
Bausch Health to Announce Third Quarter 2026 Results on October 28, 2026 - Morningstar
Stocks in play: Bausch + Lomb Corporation - Yahoo! Finance Canada
The Zacks Analyst Blog Highlights Abbott, Corcept, Precigen and Bausch Health Companies - Yahoo Finance
Bausch Health Companies Inc. (BHC) Options Chain - Yahoo! Finance Canada
Stock replaces cash board pay as Bausch Health (BHC) grants John Paulson 10,720 units. - Stock Titan
A director receives 5,789 stock units instead of cash for board service at Bausch Health (BHC). - Stock Titan
Stock replaces cash board pay as Bausch Health (BHC) grants a director 1,179 stock units. - Stock Titan
Bausch Health’s CAD 2.61 Billion Cash Position Underpins Liquidity, but Balance-Sheet Leverage Keeps Financial Discipline in Focus - kalkine.ca
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike - Zacks Investment Research
Bausch Health Companies Inc. (BHC) stock price, news, quote and history - Yahoo Finance UK
Bausch Health Companies Inc (BVF.MU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Bausch Health Companies Inc (BVF.MU) stock price, news, quote and history - Yahoo Finance Australia
How Is Bausch Health Companies (TSX:BHC) Navigating Growth Challenges? - Kalkine Media
Bausch + Lomb Corporation (BLCO.TO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Bausch Health Cash Reserves Face Scrutiny as Debt and Product Risks Persist - kalkine.ca
Bausch Health Companies Inc. (BHC.TO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Consumer Confidence Falls Amid Ongoing Geopolitical Tensions: 4 Picks - Zacks Investment Research
New Bausch class action lands in Rhode Island federal court - The Business Journals
Bausch Health Companies Inc. (TSX:BHC) Gains Momentum as Healthcare Portfolio Strength and Operational Improvements Support Investor Confidence - kalkine.ca
Acne Vulgaris Market Set for Significant Growth During the Forecast Period (2026–2036), Amid Rising Disease Burden and Therapeutic Advances | DelveInsight - GlobeNewswire Inc.
BHC4801893 Bond Profile: Coupon and Redemption - TradingView
Screening for Hidden Gem Stocks Under $20 - TradingView
Bausch Health Companies stock holds near USD 5.70 after earnings beat - AD HOC NEWS
Bausch Health Companies Inc. (BHC) Stock Price, News, Quote & History - Yahoo! Finance Canada
Can Bausch (BHC) Run Higher on Rising Earnings Estimates? - Eastern Progress
Bausch Health’s CAD 2.61 Billion Cash Position Supports Liquidity, but Balance-Sheet Leverage Keeps Financial Discipline in Focus - kalkine.ca
Why Bausch Health's Raised Outlook Matters for This S&P/TSX Composite Healthcare Stock (TSX:BHC) - kalkine.ca
Bausch Health Companies stock holds steady as analysts stick to Reduce rating - AD HOC NEWS
Body Contouring Devices Market Expands as Non-Invasive Technology Reaches Untapped Male Demographic - GlobeNewswire Inc.
Bausch Health Companies Stock Price Forecast. Should You Buy BHC? - StockInvest.us
Bausch Health (BHC) Expands Probiotic Skincare Bet To Six New Markets - Yahoo Finance
Bausch Health Companies and the Changing Healthcare Landscape - Kalkine Media
What's The Latest On Bausch Health (TSX:BHC)? - Kalkine Media
Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser - Financial Times
BHC - Finviz
PwC Will Pay $96M To Settle Valeant Investor Class Claims - Law360
Bausch Health Companies Inc (BHC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Bausch Health Companies Inc 주식 (BHC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Lenar Aimee J. | Officer |
Aug 19 '26 |
Proposed Sale |
7.03 |
36,827 |
258,894 |
0 |
| Lee Frank D. | Director |
May 19 '26 |
Sale |
5.43 |
24,456 |
132,796 |
49,339 |
| Lee Frank D. | Director |
May 19 '26 |
Proposed Sale |
5.43 |
24,456 |
132,796 |
0 |
| Carson Seana | Officer |
Mar 03 '26 |
Proposed Sale |
5.77 |
4,420 |
25,503 |
0 |
| Carson Seana | EVP, General Counsel |
Mar 03 '26 |
Sale |
5.77 |
4,420 |
25,503 |
616,761 |
| Carson Seana | EVP, General Counsel |
Mar 02 '26 |
Sale |
5.78 |
6,856 |
39,628 |
776,076 |
| Carson Seana | Officer |
Mar 02 '26 |
Proposed Sale |
5.78 |
6,856 |
39,628 |
0 |
| Carson Seana | EVP, General Counsel |
Feb 27 '26 |
Sale |
5.95 |
8,388 |
49,909 |
809,258 |
| Carson Seana | Officer |
Feb 27 '26 |
Proposed Sale |
5.95 |
8,388 |
49,909 |
0 |
| PAULSON & CO. INC. | 10% Owner |
Nov 25 '25 |
Buy |
6.25 |
2,500,000 |
15,625,000 |
73,255,869 |
1.46%
4.27%
자본화:
|
볼륨(24시간):